Showing 1171-1180 of 1576 results for "".
- Johnson & Johnson Invests in Refractive Technology Start-Up TECLenshttps://modernod.com/news/johnson-johnson-invests-in-refractive-technology-start-up-teclens/2482372/Johnson & Johnson closed a transaction to co-lead the Series A funding of TECLens, a start-up developing a nonincisional refractive correction procedure that leverages corneal cross-linking (CXL) to reshape the cornea. Financial terms of the deal were not disclo
- Ikerian Receives EU-MDR Certificate for Four Devices, its Ophthalmology Data Platform and AI Modelshttps://modernod.com/news/ikerian-receives-eu-mdr-certificate-for-four-devices-its-ophthalmology-data-platform-and-ai-models/2482328/Ikerian announced it has received a European Union Medical Device Regulation (EU-MDR) certificate as Class IIa medical devices for its RetinAI Discovery digital data platform, as well as AI-based models to identify and quantify retinal layers
- Johnson & Johnson to Debut EYE-RD Global Registry at ARVOhttps://modernod.com/news/johnson-johnson-to-debut-eye-rd-global-registry-at-arvo/2482261/Johnson & Johnson announced that eight company-sponsored presentations will be featured during the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting taking place in Seattle from May 5–9, 2024. The company's two oral presentations wil
- Johnson & Johnson Launches Tecnis PureSee Presbyopia-Correcting IOL in EMEAhttps://modernod.com/news/johnson-johnson-launches-tecnis-puresee-presbyopia-correcting-iol-in-emea/2482116/Johnson & Johnson MedTech announced that its Tecnis PureSee presbyopia-correcting IOL is now available in Europe, the Middle East, and Africa (EMEA). The Tecnis PureSee IOL features a proprietary, purely refractive design that delivers uninterrupted, high-quality, vision with high best-in-cat
- Johnson & Johnson Buys Gene Therapy Eye Portfolio from MeiraGTxhttps://modernod.com/news/johnson-johnson-buys-gene-therapy-for-x-linked-retinitis-pigmentosa-from-meiragtx/2482024/Johnson & Johnson, through its Janssen Pharmaceuticals division, has acquired the rights to investigational gene therapy botaretigene sparoparvovec (bota-vec; formerly AAV-RPGR) for patients with the inherited retinal disease X-linked retinitis pigmentosa (XLRP) from MeiraGTx.<
- Johnson & Johnson Vision Presents Data at #Academy23 on ACUVUE MAX 1-Day Contact Lenseshttps://modernod.com/news/johnson-johnson-vision-presents-data-at-academy23-on-acuvue-max-1-day-contact-lenses/2481885/Johnson & Johnson Vision will present data on the ACUVUE OASYS MAX 1-Day brand family of lenses and research on myopia progression, along with learning opportunities and support of Sight for Kids at the Academy 2023 New Orleans meeting, October 11–14. In celebration
- Johnson & Johnson Vision Announces Launch of Elita Platform to Correct Myopia with New SILK Procedurehttps://modernod.com/news/johnson-johnson-vision-announces-launch-of-elita-platform-to-correct-myopia-with-new-silk-procedure/2481802/Johnson & Johnson Vision will launch the new Elita Platform at European Society of Cataract and Refractive Surgeons (ESCRS) Congress, September 8-12, 2023, in Vienna, Austria. The Elita Platform enables surgeons to perform refractive correction on patients w
- Johnson & Johnson Vision’s Acuvue Abiliti Brand Launches Back-to-School Campaign to Address Myopiahttps://modernod.com/news/johnson-johnson-visions-acuvue-abiliti-brand-launches-back-to-school-campaign-to-address-myopia/2481762/Johnson & Johnson Vision, part of Johnson & Johnson MedTech, announced that its Acuvue Abiliti brand is initiating a Back-to-School campaign to inform parents about the growing risk of myopia and encourage them to schedule a comprehensive eye exam for their children ahead of the new schoo
- Johnson & Johnson Vision to Present and Support 43 Company-Sponsored and Investigator-Led Studies at ASCRShttps://modernod.com/news/johnson-johnson-vision-to-present-and-support-43-company-sponsored-and-investigator-led-studies-at-ascrs/2481593/Johnson & Johnson Vision will present and support 43 company-sponsored and investigator-led studies evaluating innovation, outcomes and satisfaction rates across its surgical portfolio at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Diego, May 5-8
- Johnson & Johnson Vision Receives FDA Clearance for its Elita Femtosecond Laserhttps://modernod.com/news/johnson-johnson-vision-receives-fda-clearance-for-its-elita-femtosecond-laser/2481573/Johnson & Johnson Vision announced that it has received FDA 510(k) clearance for the Elita Femtosecond Laser for the creation of LASIK flaps. Elita will be unveiled at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) in San Diego, May 5-8